Trevi Therapeutics (TRVI) Assets Average (2019 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Assets Average of $186.5 million for Q1 2026, up 71.2% year-over-year from $109.0 million in Q1 2025, and down 5.03% quarter-over-quarter from $196.4 million in Q4 2025.
Trevi Therapeutics (TRVI) Assets Average (2019 - 2026) Analysis & Trends
Trevi Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $186.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 71.2% year-over-year to $186.5 million; the TTM figure through Mar 2026 stood at $186.5 million (up 71.2% YoY), while the FY2025 annual figure was $152.2 million, up 51.94% from the prior year.
- Assets Average for Q1 2026 stood at $186.5 million, down from $196.4 million in the prior quarter.
- The five-year high for Assets Average was $203.8 million in Q3 2025, with the low at $34.4 million in Q1 2022.
- The 5-year median for Assets Average is $104.9 million (2022), against an average of $112.6 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average soared 258.74% in 2022, then slipped 29.84% in 2024.
- Trevi Therapeutics' Assets Average stood at $125.7 million in 2022, then slipped by 26.29% to $92.6 million in 2023, then retreated by 2.96% to $89.9 million in 2024, then soared by 118.45% to $196.4 million in 2025, then slipped by 5.03% to $186.5 million in 2026.
- Business Quant data shows TRVI's Assets Average at $186.5 million in Q1 2026, $196.4 million in Q4 2025, and $203.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 255.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 255.06 Mn |
| Mar 31, 2026 | 186.52 Mn |
| Dec 31, 2025 | 196.40 Mn |
| Sep 30, 2025 | 203.85 Mn |
| Jun 30, 2025 | 157.67 Mn |
| Mar 31, 2025 | 108.95 Mn |
| Dec 31, 2024 | 89.90 Mn |
| Sep 30, 2024 | 71.36 Mn |
| Jun 30, 2024 | 76.18 Mn |
| Mar 31, 2024 | 83.98 Mn |
| Dec 31, 2023 | 92.65 Mn |
| Sep 30, 2023 | 98.44 Mn |
| Jun 30, 2023 | 108.59 Mn |
| Mar 31, 2023 | 119.61 Mn |
| Dec 31, 2022 | 125.69 Mn |
| Sep 30, 2022 | 104.89 Mn |
| Jun 30, 2022 | 55.90 Mn |
| Mar 31, 2022 | 34.43 Mn |
| Dec 31, 2021 | 35.04 Mn |
| Sep 30, 2021 | 35.37 Mn |